List view / Grid view

News

Merck announces results from Phase 2b study of MK-8237, an investigational house dust mite sublingual allergen immunotherapy tablet

5 March 2014 | By

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from a Phase 2b study evaluating two doses of its investigational house dust mite sublingual immunotherapy tablet (MK-8237). The data were presented for the first time during a late-breaking oral session at the 2014 Annual Meeting…

Roche Annual General Meeting 2014

4 March 2014 | By Roche

Roche announced that its Ordinary Annual General Meeting has voted in favour of all of the Board of Directors’ proposals...

Raman images faster than ever before

4 March 2014 | By Renishaw

Renishaw’s new StreamLineHR™ Rapide option for its inVia Raman microscope enables the rapid collection of large amounts of Raman data...

B&W Tek announces agreement with LabWare for automation and reporting

3 March 2014 | By

B&W Tek, Inc., an advanced instrumentation company that delivers lab quality Raman spectroscopy solutions through user-friendly mobile platforms, is pleased to announce its newest strategic partnership with LabWare, Inc., the global leader of Laboratory Information Management Systems (LIMS) and instrument integration software products.

Teva launches ADASUVE® in U.S.

3 March 2014 | By Teva

The first and only orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults...